Pierre Sujobert - Concepedia

Author

Pierre Sujobert

Inserm ORCID

Also Known As

E-F Gautier, Laure Joseph, Murielle Roux-Sauvat, P Sujobert, P. Sujobert, Pierre Sujobert, Sujobert, Pierre

105

Publications

Citations

H-Index

Concepts

All Affiliations

Inserm Centre National de la Recherche Scientifique Hospices Civils de Lyon Assistance Publique – Hôpitaux de Paris Université Paris Cité

About

Pierre Sujobert is an author at Inserm specializing in medicine, pathology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	435
2	Cell Biology	4	4	232
3	Engineering	2	2	63
4	Health Sciences	1	1	19
5	Biostatistics	1	1	23

Pierre Sujobert

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients* Sophie Georgin‐Lavialle, Benjamin Terrier, Alexis F. Guédon, British Journal of Dermatology	2021	387
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways Jérôme Tamburini, Nicolas Chapuis, Valérie Bardet, Blood	2007	252
Essential role for the p110 isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia Pierre Sujobert Blood	2005	244
The Genetic Basis of Hepatosplenic T-cell Lymphoma Matthew McKinney, Andrea B. Moffitt, Philippe Gaulard, Cancer Discovery	2017	195
High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells Laury Poulain, Pierre Sujobert, Florence Zylbersztejn, Leukemia Hematological MalignancyMolecular PharmacologyG6pd InhibitionGlycolysis AddictionMedicine	2017	140
Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience Ava Diarra, Nicolas Duployez, Élise Fournier, Blood Advances	2021	138
Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia Pierre Sujobert, Laury Poulain, Étienne Paubelle, Cell Reports	2015	104
Exome sequencing identifies recurrent <i>BCOR</i> alterations and the absence of <i>KLF2</i> , <i>TNFAIP3</i> and <i>MYD88</i> mutations in splenic diffuse red pulp small B-cell lymphoma Laurent Jallades, Lucile Baseggio, Pierre Sujobert, Haematologica	2017	72
Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of <i>ASXL1</i> mutations: a FIM study Damien Luque Paz, Jérémie Riou, Emmanuelle Verger, Blood Advances	2021	70
Toward a pathophysiology inspired treatment of VEXAS syndrome Maël Heiblig, Bhavisha A. Patel, Emma M. Groarke, Seminars in Hematology MedicineVexas SyndromeTherapeutic EfficacyExperimental TherapeuticPharmacotherapy	2021	68

Page 1